Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

Market Cap	9.00B +80.9%
Revenue (ttm)	3.95B +70.3%
Net Income	397.61M +46.5%
EPS	0.20 +48.4%
Shares Out	2.00B
PE Ratio	22.67
Forward PE	15.30
Dividend	0.04 (0.85%)
Ex-Dividend Date	n/a

Volume	19,569,490
Average Volume	42,324,934
Open	4.710
Previous Close	4.710
Day's Range	4.470 - 4.770
52-Week Range	3.022 - 5.120
Beta	0.27
RSI	68.30
Earnings Date	Mar 15, 2026

About EGX:RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of ...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Country: Egypt
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: RMDA

Financial Performance

In 2024, EGX:RMDA's revenue was 2.77 billion, an increase of 44.03% compared to the previous year's 1.92 billion. Earnings were 363.84 million, an increase of 62.79%.